| Iupac Name: | (2S)-6-Amino-2-(2S)-2-(2R)-2-amino-5-(diaminomethylideneamino)pentanoylamino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoylamino]-N-[(2''S'')-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide |
| Cas Number: | 736992-21-5 |
| Pubchem: | 11764719 |
| Unii: | 87GWG91S09 |
| Kegg: | D10925 |
| Synonyms: | H-D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH2; D-Arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide |
| C: | 32 |
| H: | 49 |
| N: | 9 |
| O: | 5 |
| Stdinchikey: | SFVLTCAESLKEHH-WKAQUBQDSA-N |
| Stdinchi: | 1S/C32H49N9O5/c1-19-15-22(42)16-20(2)23(19)18-27(41-29(44)24(34)11-8-14-38-32(36)37)31(46)39-25(12-6-7-13-33)30(45)40-26(28(35)43)17-21-9-4-3-5-10-21/h3-5,9-10,15-16,24-27,42H,6-8,11-14,17-18,33-34H2,1-2H3,(H2,35,43)(H,39,46)(H,40,45)(H,41,44)(H4,36,37,38)/t24-,25+,26+,27+/m1/s1 |
Elamipretide (also known as SS-31,, MTP-131 and Bendavia)[1] [2] is a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that appears to reduce the production of toxic reactive oxygen species and stabilize cardiolipin.[3]
Stealth Peptides, a privately held company, was founded in 2006 to develop intellectual property licensed from several universities including elamipretide; it subsequently changed its name to Stealth BioTherapeutics.[4] [5]
As of November 2017 Stealth had obtained an orphan designation in the US for use in mitochondrial myopathy and had started a Phase III trial in that indication.[2] As of January 2020, trial expectations were not met.[6]